nefazodone has been researched along with Premenstrual Syndrome in 7 studies
nefazodone: may be useful as an opiate adjunct
Premenstrual Syndrome: A combination of distressing physical, psychologic, or behavioral changes that occur during the luteal phase of the menstrual cycle. Symptoms of PMS are diverse (such as pain, water-retention, anxiety, cravings, and depression) and they diminish markedly 2 or 3 days after the initiation of menses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nefazodone, a new phenylpiperazine antidepressant agent with serotonin type 2 antagonism and serotonin reuptake inhibition, was evaluated in two patient groups to determine its effectiveness in reducing the symptoms of premenstrual syndrome (PMS)." | 9.07 | Nefazodone in the treatment of premenstrual syndrome: a preliminary study. ( Denis, A; Freeman, EW; Pfeifer, S; Rickels, K; Sondheimer, SJ; Weil, S, 1994) |
| "Nefazodone is a new antidepressant exhibiting properties of selective serotonin reuptake inhibition and serotonin-2 receptor antagonism." | 5.29 | Probable nefazodone-induced mania in a patient with unreported bipolar disorder. ( Blaisdell, GD; Jermain, DM; Zaphiris, HA, 1996) |
| "Nefazodone, a new phenylpiperazine antidepressant agent with serotonin type 2 antagonism and serotonin reuptake inhibition, was evaluated in two patient groups to determine its effectiveness in reducing the symptoms of premenstrual syndrome (PMS)." | 5.07 | Nefazodone in the treatment of premenstrual syndrome: a preliminary study. ( Denis, A; Freeman, EW; Pfeifer, S; Rickels, K; Sondheimer, SJ; Weil, S, 1994) |
| "Lifetime psychiatric illness is also common in women with PMDD, and although mood disorders predominate, past histories of anxiety disorders are also common, further suggesting an association between PMDD and anxiety disorders." | 2.40 | Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders? ( Yonkers, KA, 1997) |
| " It offers advantages over daily dosing throughout the menstrual cycle, such as reduced incidence and severity of side-effects, and avoids the stigma that may accompany the continuous use of psychopharmacological treatment, with the advantage that compliance may be improved." | 1.31 | Intermittent, luteal phase nefazodone treatment of premenstrual dysphoric disorder. ( Finkel, B; Katz, S; Kodesh, A; Lerner, AG; Sigal, M, 2001) |
| "Nefazodone is a new antidepressant exhibiting properties of selective serotonin reuptake inhibition and serotonin-2 receptor antagonism." | 1.29 | Probable nefazodone-induced mania in a patient with unreported bipolar disorder. ( Blaisdell, GD; Jermain, DM; Zaphiris, HA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Freeman, EW | 1 |
| Rickels, K | 1 |
| Sondheimer, SJ | 1 |
| Denis, A | 1 |
| Pfeifer, S | 1 |
| Weil, S | 1 |
| Zaphiris, HA | 1 |
| Blaisdell, GD | 1 |
| Jermain, DM | 1 |
| Yonkers, KA | 1 |
| Fogelson, DL | 1 |
| Kodesh, A | 1 |
| Katz, S | 1 |
| Lerner, AG | 1 |
| Finkel, B | 1 |
| Sigal, M | 1 |
| Landén, M | 1 |
| Eriksson, O | 1 |
| Sundblad, C | 1 |
| Andersch, B | 1 |
| Naessén, T | 1 |
| Eriksson, E | 1 |
| Miller, MN | 1 |
| Miller, BE | 1 |
| Chinouth, R | 1 |
| Coyle, BR | 1 |
| Brown, GR | 1 |
1 review available for nefazodone and Premenstrual Syndrome
| Article | Year |
|---|---|
Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders?
Topics: 1-Naphthylamine; Adult; Age of Onset; Anxiety; Anxiety Disorders; Buspirone; Carbon Dioxide; Comorbi | 1997 |
2 trials available for nefazodone and Premenstrual Syndrome
| Article | Year |
|---|---|
Nefazodone in the treatment of premenstrual syndrome: a preliminary study.
Topics: Adolescent; Adult; Antidepressive Agents; Drug Administration Schedule; Female; Humans; Piperazines; | 1994 |
Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo.
Topics: Adult; Buspirone; Double-Blind Method; Female; Humans; Piperazines; Premenstrual Syndrome; Psychiatr | 2001 |
4 other studies available for nefazodone and Premenstrual Syndrome
| Article | Year |
|---|---|
Probable nefazodone-induced mania in a patient with unreported bipolar disorder.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bipolar Disorder; Depres | 1996 |
Nefazodone- and/or sodium tetradecyl sulfate-associated leukopenia, fever, and shaking chills in a patient with premenstrual dysphoric disorder.
Topics: Antidepressive Agents, Second-Generation; Female; Fever; Humans; Leukopenia; Middle Aged; Piperazine | 1997 |
Intermittent, luteal phase nefazodone treatment of premenstrual dysphoric disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Female; Humans; Luteal Phase; Piperazines; Premenst | 2001 |
Increased premenstrual dosing of nefazodone relieves premenstrual magnification of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Dose-Response Relationship, Drug; Female; Humans; P | 2002 |